Video Player is loading.
10 seconds
Playback speed
SITC 2022 on the EO2401 Microbiome Derived Therapeutic Vaccine + Nivo +/- Standard Continuous/Low-Dose Symptom Directed Bev in Recurrent Glioblastoma: Phase 1-2 EOGBM1-18/ROSALIE Study
By
Dana-Farber Cancer Institute
FEATURING
David Reardon
By
Dana-Farber Cancer Institute
FEATURING
David Reardon
Comments 0
Login to view comments.
Click here to Login